Business
Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering
Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering
About this update from Jupiter Neurosciences, Inc.
[{"type":"text","content":"Cash Runway Extended to Finance the Parkinson’s Program; Debt Paydown Improves Shareholder Equity Position Jupiter, FL, May 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (\"Jupiter\" or the \"Company\"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced the closing of its registered direct offering, pursuant to the securities purchase agreements with certain investors, for the purchase and sale of 7,142,858 shares of common stock in a registered direct offering. The gross proceeds of the offering were approximately $2.0 million (the \"Offering\"). “Yesterday's capital raise helps the Company prepare for key milestones anticipated in the next year,” said Christer Rosén, Chairman and CEO of Jupiter Neurosciences. “We were able to significantly reduce our debt, which improves our balance sheet; and with this capital in hand, we can comfortably execute on the Parkinson’s Phase 2a trial and work towards the consummation of the transaction with PharmALA (ALA-002- MDMA). With a cleaner capital structure of the company and additional cash in hand, we believe that we are well positioned for future financing opportunities.” A prospectus supplement describing the terms of the proposed registered direct offering was filed with the SEC and is available on the SEC’s website at http://www.sec.gov. A copy of the prospectus supplement and accompanying base prospectus relating to the offering may be obtained, when available, from D. Boral Capital LLC, 590 Madison Avenue, 39th Floor, New York, NY 10022, or by telephone at (212) 404-7002, or by email at [email protected]. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Clinical Trial Details Jupiter’s RESET (RESvEraTrol in Parkinson’s Disease) is active on www.clinicaltrials.gov, details here: Study Details | NCT07592767 | RESvEraTrol in Parkinson's Disease (RESET) | ClinicalTrials.gov. The trial is a multi-center, randomized, double-blind, placebo-controlled Phase 2a study designed to evaluate the JOTROL™...